Sugi Predict

Sugi Predict / Compounds / SCHEMBL23218802

SCHEMBL23218802

SCHEMBL23218802

CCOC(=O)c1coc2c(OCc3ccn(C)n3)cc(Br)cc12

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ JMJD6 Q6NYC1 2/20 0.42
▸ GRM2 Q14416 1/20 0.38
▸ ALDH1A1 P00352 1/20 0.38
▸ SMN1; SMN2 Q16637 1/20 0.38
▸ NPC1 O15118 2/20 0.36
▸ RAB9A P51151 2/20 0.36
▸ MEN1 O00255 1/20 0.36
▸ KMT2A Q03164 1/20 0.36
▸ RXFP1 Q9HBX9 4/20 0.36
▸ LMNA P02545 2/20 0.36
▸ MAPK1 P28482 2/20 0.35
▸ MAOB P27338 1/20 0.35
▸ NPSR1 Q6W5P4 2/20 0.35
▸ GABRA1 P14867 1/20 0.35
▸ GABRB1 P18505 1/20 0.35
▸ GABRA3 P34903 1/20 0.35
▸ GABRB2 P47870 1/20 0.35
▸ KDM4E B2RXH2 1/20 0.35
▸ ALOX5AP P20292 2/20 0.34
▸ ELANE P08246 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29591204 1.00 JMJD6 (0.42) JMJD6GRM2ALDH1A1SMN1; SMN2NPC1
SCHEMBL29852863 0.82 MAOB (0.41) ALDH1A1SMN1; SMN2NPC1RAB9AMEN1
SCHEMBL29591301 0.82 MAOB (0.41) ALDH1A1SMN1; SMN2NPC1RAB9AMEN1
SCHEMBL23218392 0.82 MAOB (0.41) ALDH1A1SMN1; SMN2NPC1RAB9AMEN1
SCHEMBL23218305 0.81 TBXAS1 (0.42) JMJD6GRM2SMN1; SMN2NPSR1ALOX5AP
SCHEMBL23218736 0.81 GRM2 (0.39) GRM2ALOX5AP
SCHEMBL29852957 0.80 PIM1 (0.52) ALDH1A1SMN1; SMN2MEN1KMT2ARXFP1
SCHEMBL23218355 0.80 PIM1 (0.52) ALDH1A1SMN1; SMN2MEN1KMT2ARXFP1
SCHEMBL23219048 0.78 RXFP1 (0.36) ALDH1A1SMN1; SMN2NPC1RAB9AMEN1
SCHEMBL29853169 0.78 RXFP1 (0.36) ALDH1A1SMN1; SMN2NPC1RAB9AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12558341-B2 Oral complement factor D inhibitors BIOCRYST PHARMACEUTICALS, INC. (US) 2026-02-24 — — US disclosed
US-20250186391-A1 ORAL COMPLEMENT FACTOR D INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION 2025-06-12 — — US disclosed
EP-4041238-A1 ORAL COMPLEMENT FACTOR D INHIBITORS Biocryst Pharmaceuticals, Inc. (US) 2022-08-17 — — EP disclosed
CN-114502168-A Oral complement factor D inhibitors 拜奥克里斯特制药公司 2022-05-13 — — CN disclosed
WO-2021072198-A1 ORAL COMPLEMENT FACTOR D INHIBITORS BIOCRYST PHARMACEUTICALS, INC. (US) 2021-04-15 — — WO disclosed
WO-2021072198-A1 ORAL COMPLEMENT FACTOR D INHIBITORS BIOCRYST PHARMACEUTICALS, INC. (US) 2021-04-15 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12558341-B2 Oral complement factor D inhibitors CFD, CFH, CFB JMJD6 3686/4885GRM2 4638/4885ALDH1A1 2667/4885
US-20250186391-A1 ORAL COMPLEMENT FACTOR D INHIBITORS CFD, CFH, CFB JMJD6 4765/4885GRM2 4857/4885ALDH1A1 3142/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.